Beyond hormone therapy for prostate cancer with PARP inhibitors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer.The Journal of experimental medicine · 2022
   Article
2. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.Oncotarget · 2017
   Article
3. Regulators of homologous recombination repair as novel targets for cancer treatment.Frontiers in genetics · 2015
   Review
4. Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?Protein & cell · 2014
   Review
5. Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.British journal of cancer · 2012
   Article
6. The role of BRCA1 and BRCA2 in prostate cancer.Asian journal of andrology · 2012
   Review
7. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
   Article
8. Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.Nature reviews. Urology · 2012
   Review

Corrections and comments

• Commented on by
  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.2011

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.